SMAD4 and exocrine pancreatic carcinoma: Therefore, we were interested in whether knocking out SMAD4 in the PANC-1 cell line, which has been found to be associated with a worse prognosis in pancreatic carcinoma, would affect resistance to MTO [52,53,54].